still execut despit
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
conclus anoth solid quarter share sell presum part sell expectedli
strong evolv fear humira biosimilar pois enter eu next quarter well ema
approv sandoz biosimilar humira chmp recommend biosimilar humira
start work way back toward top large-cap pick continu execut
articul nt/lt growth strategi despit emerg humira biosimilar
strong perform across board upward revis guidanc guidanc provid
see highli confid abil sustain strong growth pull right trigger
right time achiev buy-back author left
amount time spent articul defens humira rebat patent
compani outlook respons multipl question topic expect
product perform highlight see humira us growth high singl
digit volum price ou still abl grow despit competitor class fx
benefit mavyret still benefit wareh global product sale perform
volum growth
expect new products/ind now/direct humira biosimilar competit
emphas emerg profil venclexta particularli aml respons rate seen
set combo hypomethyl agent file aml bellini
myeloma expect also flag emerg profil cll sale report
orilissa confid outlook multi-billion dollar product evalu add-back therapi
goal remov recommend limit durat use low dose high dose
model updat adjust earn increas orilissa sale estim given
guidanc sale chang pt
track respect beat/miss
commentari around product serial around quarter includ
line revenueglob oper sale fx oper growth volumelow doubl digit single-digit growth digit growth exclud destock leader across categoriesrobust market ra spa psoriasi crohn uc posit vari retail inventori destock larg specialti pharci exclud impact growth ex-u benefit shipment time exclud impact growth prescript growth lead global therapi across approv indications tender time inventori half month half month half month half monthglob oper cll market share leader across line therapycl clear market report mavyret/hcvcommentarycontribut contract cycl esp sharepar acccess across cover live usclos us market share access cover live mavyret sale total primarili daa failur patient japan mavyret market lead posit us strong leadership posit number ex-u market mavryet oper oper partnership partnership partnership account exchang hedg benefit time compens compani reportshumiraimbruvicaabbv histor quarter perform commentaryvenclextaadjust tax rateadjust edj gross marginadjust salesadjust sg salesoper margin juli
serial guidanc updat
growth fx minim fx compound-annual-growth-rate fx fx benefit oper fx fx oper oper fx annual mid/high teensmid/high teen fy guidanc unchang qhigh teenslow teen ou annual mid-singl fx approach mid-mid-singlepeak qmid singlemid-single-digit prior w/w annual fy guidanc unchangedoth product annual mavyret deliv multi-billion peakglob hcv equal split us ou market creon growth duodopa androgel zinbryta synagi lupron synthroid flatproject full year hcv sale hcv approach us sale global hcv global orilissa margin weak usd may impact sale sale margin expens fy guidanc unchangedadjust tax rate increas next year approach also approach ep y/i y/i y/i y/i midpoint non-cash non-cash sourc compani reportsannu guidanc start year unless indic juli
help
josh ami
deriv pt use dcf discount rate termin growth rate discount
rate standard rate appli across derisk biopharma compani reflect believ appropri return
sharehold termin growth rate reflect durabl natur compani biolog franchis
clearli humira domin product model still assum repres total model revenu
current framework biosimilar adopt chang humira method use patent fall multipl biosimilar
launch simultan creat pent-up precipit impact sale share could suffer rova-t elagolix
import pipelin program either stumbl share could see modest downsid
articl articl
time dissemin juli et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu shenston huang primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
